相似文献
1
Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction.
Circulation. 2011 Feb 8;123(5):551-65. doi: 10.1161/CIRCULATIONAHA.109.912568.
2
Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction.
Trends Cardiovasc Med. 2011 May;21(4):105-12. doi: 10.1016/j.tcm.2012.03.007.
3
Candidate circulating biomarkers for the cardiovascular disease continuum.
Curr Pharm Des. 2008;14(24):2445-61. doi: 10.2174/138161208785777388.
4
Biomarkers of cardiovascular risk--matters of prediction and precision.
Clin Chem Lab Med. 2010 Dec;48(12):1683-4. doi: 10.1515/CCLM.2010.357.
5
Editor's presentation: Do we really need biomarkers for cardiovascular risk prediction?
Eur J Prev Cardiol. 2020 Apr;27(6):563-565. doi: 10.1177/2047487320917001.
6
Cardiovascular disease risk prediction in women: is there a role for novel biomarkers?
Clin Chem. 2014 Jan;60(1):88-97. doi: 10.1373/clinchem.2013.202796. Epub 2013 Oct 7.
7
Biomarkers of cardiovascular disease: molecular basis and practical considerations.
Circulation. 2006 May 16;113(19):2335-62. doi: 10.1161/CIRCULATIONAHA.104.482570.
8
Circulating biomarkers in cardiovascular disease.
Dis Markers. 2009;26(5-6):197-8. doi: 10.3233/DMA-2009-0644.
9
High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome.
Clin Chem. 2005 Mar;51(3):504-5. doi: 10.1373/clinchem.2004.044990.
10
Biomarkers in cardiovascular diseases: how can the "-omics" revolution be applicable at the bedside. Introduction.
Prog Cardiovasc Dis. 2012 Jul-Aug;55(1):1-2. doi: 10.1016/j.pcad.2012.06.001.
引用本文的文献
1
Cascaded Self-Supervision to Advance Cardiac MRI Segmentation in Low-Data Regimes.
Bioengineering (Basel). 2025 Aug 12;12(8):872. doi: 10.3390/bioengineering12080872.
2
Integration of Left Atrial Function Assessment, Genetic Risk, and Clinical Risk Factors Improves Prediction of Incident Atrial Fibrillation.
J Am Heart Assoc. 2025 May 20;14(10):e037145. doi: 10.1161/JAHA.124.037145. Epub 2025 May 13.
3
Coronary artery disease is associated with particular change of serum metabolome: a case-control study.
Metabolomics. 2025 Apr 26;21(3):57. doi: 10.1007/s11306-025-02253-z.
4
Heart failure and microvascular dysfunction: an in-depth review of mechanisms, diagnostic strategies, and innovative therapies.
Ann Med Surg (Lond). 2024 Dec 24;87(2):616-626. doi: 10.1097/MS9.0000000000002971. eCollection 2025 Feb.
5
Artificial Intelligence in Ischemic Heart Disease Prevention.
Curr Cardiol Rep. 2025 Feb 1;27(1):44. doi: 10.1007/s11886-025-02203-0.
6
Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart Disease.
J Am Heart Assoc. 2024 Nov 5;13(21):e034367. doi: 10.1161/JAHA.123.034367. Epub 2024 Oct 25.
7
Optical coherence tomography angiography in cardiovascular disease.
Prog Cardiovasc Dis. 2024 Nov-Dec;87:60-72. doi: 10.1016/j.pcad.2024.10.011. Epub 2024 Oct 21.
8
Unveiling TIMPs: A Systematic Review of Their Role as Biomarkers in Atherosclerosis and Coronary Artery Disease.
Diseases. 2024 Aug 2;12(8):177. doi: 10.3390/diseases12080177.
9
Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
Chest. 2024 Dec;166(6):1511-1531. doi: 10.1016/j.chest.2024.06.3824. Epub 2024 Aug 16.
10
Risk estimation for the primary prevention of cardiovascular disease: considerations for appropriate risk prediction model selection.
Lancet Glob Health. 2024 Aug;12(8):e1343-e1358. doi: 10.1016/S2214-109X(24)00210-9.
本文引用的文献
1
Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study.
J Am Coll Cardiol. 2010 Oct 19;56(17):1407-14. doi: 10.1016/j.jacc.2010.06.029.
2
Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study.
J Am Coll Cardiol. 2010 Oct 19;56(17):1397-406. doi: 10.1016/j.jacc.2010.06.030.
3
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Am J Cardiol. 2010 Jul 15;106(2):204-9. doi: 10.1016/j.amjcard.2010.03.018. Epub 2010 Jun 10.
4
By Jove! What is a clinician to make of JUPITER?
Arch Intern Med. 2010 Jun 28;170(12):1073-7. doi: 10.1001/archinternmed.2010.189.
5
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.
Circulation. 2010 Jun 8;121(22):2388-97. doi: 10.1161/CIRCULATIONAHA.109.901413. Epub 2010 May 24.
6
Separating the contenders from the pretenders: competitive high-throughput biomarker screening in large population-based studies.
Circulation. 2010 Jun 8;121(22):2381-3. doi: 10.1161/CIRCULATIONAHA.110.953463. Epub 2010 May 24.
7
Multiple biomarkers for predicting cardiovascular events: lessons learned.
J Am Coll Cardiol. 2010 May 11;55(19):2092-5. doi: 10.1016/j.jacc.2010.02.019.
8
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
Lancet. 2010 May 1;375(9725):1536-44. doi: 10.1016/S0140-6736(10)60319-4.
9
What makes a good predictor?: the evidence applied to coronary artery calcium score.
JAMA. 2010 Apr 28;303(16):1646-7. doi: 10.1001/jama.2010.503.
10
Coronary artery calcium score and risk classification for coronary heart disease prediction.
JAMA. 2010 Apr 28;303(16):1610-6. doi: 10.1001/jama.2010.461.
Zotero 插件